The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study

被引:56
作者
Saw, Jacqueline [1 ]
Madsen, Esben Hjorth [4 ]
Chan, Sammy [4 ]
Maurer-Spurej, Elisabeth [2 ,3 ,4 ,5 ]
机构
[1] Vancouver Gen Hosp, Div Cardiol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Ctr Blood Res, Vancouver, BC V5Z 1M9, Canada
[4] Canadian Blood Serv, Vancouver, BC, Canada
[5] St Pauls Hosp, Div Cardiol, Vancouver, BC V6Z 1Y6, Canada
关键词
aspirin; clopidogrel; platelet aggregation; platelet activation; inflammation;
D O I
10.1016/j.jacc.2008.08.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives This study was designed to evaluate the effects of long-term clopidogrel and aspirin administration on platelet aggregation, activation, and inflammation. Background Clopidogrel resistance was described in 15% to 30% of patients with short-term therapy, but its antiplatelet effects with long-term therapy is unknown. Methods We performed a prospective study of patients undergoing coronary stenting who were on aspirin for >= 5 days but not previously on clopidogrel. Clopidogrel 600 mg was given before stenting. Clopidogrel 75 mg/day and aspirin 325 mg/day were continued for 1 year. Light-transmittance aggregometry with 5-mu mol/l adenosine diphosphate and 1-mmol/l arachidonic acid stimulation; VerifyNow clopidogrel and aspirin assays; platelet activation receptor expression of CD40L, CD62P, and PAC-1 (antibody against activated glycoprotein IIb/IIIa); and inflammatory markers of soluble CD40L and P-selectin, high-sensitivity C-reactive protein, interleukin-10, and interleukin-18 were measured at baseline; 1 day; and 1, 6, and 12 months. Our primary analysis compared light-transmittance aggregometry aggregation at 1 versus 12 months. Results We enrolled 26 patients who completed a 1-year follow-up. Maximal platelet adenosine diphosphate-stimulated aggregation was 61.8 +/- 25.9% at baseline, 22.1 +/- 18.3% at 1 day, 30.6 +/- 16.8% at 1 month, 29.0 +/- 13.3% at 6 months, and 26.7 +/- 13.6% at 12 months (p = 0.099 for 12 months vs. 1 month). VerifyNow clopidogrel platelet inhibition was similar at 12 months versus 1 month (38.9 +/- 19.7% vs. 45.6 +/- 26.7%, p = 0.578). Likewise, there was no difference in aspirin's effects on platelet aggregation at 12 months versus 1 month. In contrast, platelet activation receptor expression of CD40L, CD62P, and PAC-1 were higher at 12 months versus 1 month. Conclusions Our pilot study showed no attenuation of clopidogrel's effects on platelet aggregation with long-term administration. However, platelet activation receptor expression increased with time and should be further evaluated. (J Am Coll Cardiol 2008; 52: 1826-33) (c) 2008 by the American College of Cardiology Foundation
引用
收藏
页码:1826 / 1833
页数:8
相关论文
共 9 条
[1]   Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial [J].
Bhatt, Deepak L. ;
Flather, Marcus D. ;
Hacke, Werner ;
Berger, Peter B. ;
Black, Henry R. ;
Boden, William E. ;
Cacoub, Patrice ;
Cohen, Eric A. ;
Creager, Mark A. ;
Easton, J. Donald ;
Hamm, Christian W. ;
Hankey, Graeme J. ;
Johnston, S. Claiborne ;
Mak, Koon-Hou ;
Mas, Jean-Louis ;
Montalescot, Gilles ;
Pearson, Thomas A. ;
Steg, P. Gabriel ;
Steinhubl, Steven R. ;
Weber, Michael A. ;
Fabry-Ribaudo, Liz ;
Hu, Tingfei ;
Topol, Eric J. ;
Fox, A. A. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (19) :1982-1988
[2]   Profile and prevalence of aspirin resistance in patients with cardiovascular disease [J].
Gum, PA ;
Kottke-Marchant, K ;
Poggio, EC ;
Gurm, H ;
Welsh, PA ;
Brooks, L ;
Sapp, SK ;
Topol, EJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (03) :230-235
[3]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913
[4]   DEVELOPMENT OF ASPIRIN RESISTANCE IN PERSONS WITH PREVIOUS ISCHEMIC STROKE [J].
HELGASON, CM ;
BOLIN, KM ;
HOFF, JA ;
WINKLER, SR ;
MANGAT, A ;
TORTORICE, KL ;
BRACE, LD .
STROKE, 1994, 25 (12) :2331-2336
[5]   CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells [J].
Henn, V ;
Slupsky, JR ;
Gräfe, M ;
Anagnostopoulos, I ;
Förster, R ;
Müller-Berghaus, G ;
Kroczek, RA .
NATURE, 1998, 391 (6667) :591-594
[6]   The influence of selective serotonin reuptake inhibitors on human platelet serotonin [J].
Maurer-Spurej, E ;
Pittendreigh, C ;
Solomons, K .
THROMBOSIS AND HAEMOSTASIS, 2004, 91 (01) :119-128
[7]   Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement [J].
Müller, I ;
Besta, F ;
Schulz, C ;
Massberg, S ;
Schönig, A ;
Gawaz, M .
THROMBOSIS AND HAEMOSTASIS, 2003, 89 (05) :783-787
[8]   Variation and importance of aspirin resistance in patients with known cardiovascular disease [J].
Poulsen, Tina Svenstrup ;
Kristensen, Soren Risom ;
Korsholm, Lars ;
Haghfelt, Torben ;
Jorgensen, Bo ;
Licht, Peter Bjorn ;
Mickley, Hans .
THROMBOSIS RESEARCH, 2007, 120 (04) :477-484
[9]   Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients [J].
Pulcinelli, FM ;
Pignatelli, P ;
Celestini, A ;
Riondino, S ;
Gazzaniga, PP ;
Violi, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (06) :979-984